What You Should Know:– Flatiron Health, a leading technology company focused on improving cancer care announced a strategic partnership with Exact Sciences, a pioneer in cancer screening and diagnostics to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease (MRD) test, Oncodetect™.– The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.Leverage Real-World Data and Community Oncology Settings to Advance Cancer CareMRD testing is a rapidly evolving field in oncology, with the potential to transform cancer care by detecting residual disease after treatment and guiding personalized treatment decisions. However, generating robust clinical evidence for MRD tests can be challenging and time-consuming.This partnership aims to address this challenge by:Leveraging real-world data: Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting.Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting. Focusing on diverse patient populations: Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials.Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials. Accelerating evidence generation: Employing a novel prospective clinical evidence generation platform and pragmatic study design to expedite the research process.First Patient EnrolledThe partnership has already achieved a significant milestone with the enrollment of the first patient in the study in under six months from conception. This rapid progress highlights the strong collaboration and commitment to execution between Flatiron Health and Exact Sciences.“Our partnership with Exact Sciences leverages Flatiron’s next-generation prospective evidence platform, which we designed to address critical evidence gaps via studies embedded into routine care, with unprecedented speed,” said Alex Deyle, general manager, Clinical Research, Flatiron Health. “Our in-house team of experts, experienced site network, fit-for-purpose research operations, and cutting-edge technology that focuses on reducing site burden, has enabled us to run more efficient and representative prospective studies.”

Retirement Wealth Solutions LLC invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS).

Notably, Exact Sciences is also working on its own blood-based test for colorectal cancer screening.